Zephyr Presents Award Winning Research at the 2016 Meetings of the ATS, AADSM an APSS

Zephyr Presents Award Winning Research at the 2016 Meetings of the ATS, AADSM an APSS

FOR IMMEDIATE RELEASE: May 16, 2016

Zephyr Presents Award Winning Research at the 2016 Meetings of the ATS, AADSM and APSS

(Calgary, Alberta, May 16, 2016) – Each June, the AADSM Research Committee recognizes outstanding research in dental sleep medicine. This year, Dr. John Remmers, Zephyr Sleep Technologies’ Chief Medical Officer has been selected as a recipient of the AADSM Clinical Research Award and the AADSM Clinical Excellence Award based on the scientific merit and research excellence demonstrated in the abstract “A Mandibular Positioning Home Sleep Test Prospectively Predicts Outcome of Oral Appliance Therapy for OSA Using Retrospectively Derived Decision Criteria”.

In addition, Dr. Nikola Vranjes, principal dental investigator in this clinical trial using the auto-titrating mandibular positioner (AMP) technology, has been selected as a recipient of the AADSM Clinical Research Award for the scientific merit of the abstract “A New Oral Appliance Titration Protocol using the MicrO2 Sleep Device and Mandibular Positioning Home Sleep Test”.

These awards will be presented to Dr. Remmers and Dr. Vranjes at this year’s AADSM meeting in Denver.

In addition, Zephyr is pleased to announce the acceptance of the following abstracts for presentation at the upcoming international meetings:

  • American Thoracic Society (ATS) – May 13-18, San Francisco CA – “Prediction of Outcome with Oral Appliance Therapy for Obstructive Sleep Apnea Using In-home Mandibular Titration”. These research findings will be presented on May 18th by Dr. Remmers during a poster presentation in a thematic poster session entitled: Don’t be a Do-Badder: New Interventions for OSA.
  • American Academy of Dental Sleep Medicine (AADSM) – June 9-11, Denver CO – “A Mandibular Positioning Home Sleep Test Prospectively Predicts Outcome of Oral Appliance Therapy for OSA Using Retrospectively Derived Decision Criteria” and “A New Oral Appliance Titration Protocol using the MicrO2 Sleep Device and Mandibular Positioning Home Sleep Test”. These research findings will be presented on June 10th by Dr. Remmers and Dr. Vranjes during poster and oral presentations.
  • Associated Professional Sleep Societies (APSS) – June 11-15, Denver CO – “Prediction of Outcome With Oral Appliance Therapy for Obstructive Sleep Apnea Using In-home Mandibular Titration”. These research findings will be reviewed by Dr. Remmers at the poster presentations on June 12th.

Dr. Remmers’ extensive research and innovation in the field of sleep medicine is world-renowned. Frustrated with the field’s inability to embrace alternatives to CPAP, Dr. Remmers and colleagues from the University of Calgary and local business leaders co-founded Zephyr Sleep Technologies in 2010 to create innovative ways to diagnose and treat illnesses relating to sleep-disordered breathing.

Oral appliance therapy (OAT) has emerged as a “patient-preferred” treatment alternative to CPAP, but lacks a standard and scientifically-validated method to select patients for this treatment. Patient selection for OAT is critical as it is generally accepted that it is only efficacious in about 60% of the cases.

In 2012, Zephyr Sleep Technologies released MATRx, an in-lab OAT titration system. This innovative, leading-edge technology is fast becoming the standard in selecting patients for OAT and is being used by sleep physicians in hundreds of sleep centers across North America to predict OAT response and an efficacious target protrusion for the creation of a custom oral appliance. To date, the MATRx in-lab study has been performed on approximately 10,000 patients and at prestigious sites including: Kaiser Permante, Swedish Medical Center, New York University Sleep Disorder Center, Stanford University Hospital and the University of Chicago Hospital.

MATRx is a patient selection tool. It is the only validated diagnostic device that can predict therapeutic outcome with a custom-fitted oral appliance after a single-night of study in a polysomnographic lab. “By selecting patients for OAT with MATRx, MDs are now able to confidently prescribe an oral appliance to treat OSA” states Dr. Remmers, “once we take a patient’s preference for OAT and higher adherence into account, we will be able to treat a greater number of patients”.

Zephyr’s proprietary “AMP technology” is a significant innovation providing the opportunity to bring the power of MATRx to the patient’s home. “By opening the door to bringing MATRx to the patient’s home, we believe we will increase accessibility and provide structural cost benefit to the healthcare system” states Paul Cataford, CEO and Co-founder of Zephyr, “we have a lot of exciting announcements coming over the next few months, so, stay tuned”.

ABOUT ZEPHYR
Zephyr Sleep Technologies is a privately held product development company that researches, designs, develops, manufactures and distributes innovative and scientifically-validated medical devices focused on the diagnosis and treatment of certain sleep disorders. Zephyr’s products and technologies are used world-wide by sleep labs, technicians, physicians, dentists, and leading-edge sleep researchers. MATRx was developed by Zephyr and is based on and powered by the proprietary and patented technology known as OATRx. Zephyr is based in Calgary, Alberta.

For more information, please visit www.zephyrsleep.com:
Zephyr Sleep Technologies
###

%d bloggers like this: